← Back to patent-cliff list
Bilastine/Montelukast
Tier C — Watch / tradeBilastine/Montelukast
Synokem Pharmaceuticals Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：HRH1, CYSLTR1
Indications (approved)：Allergic rhinitis
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bilastine/Montelukast?
Approved indications include: Allergic rhinitis.
When does the Bilastine/Montelukast patent expire?
No public expiry year is available for Bilastine/Montelukast yet; this page updates once verified.
How do I get a quote for Bilastine/Montelukast intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21